Detection of oncogenic HPV and identification of 72Arg polymorphic p53 by in situ PCR for clinical routine purposes.

Massimo Realacci, Giulietta Anna Perrone, Patrizio Sale, Marco Tafani, Maura Di Vito, Raffaele Perrone-Donnorso, Giancarlo Zotti, Matteo A Russo

Journal: Anticancer research 2006;26(4B):3095-103

PMID: 16886640

Abstract

BACKGROUND

Ano-genital carcinoma is a polyfactorial and polygenic disease. Certain strains of human papillomavirus (HPV) have been detected in a high percentage of patients. It has been suggested that p53 polymorphisms may be relevant for the interaction with viral proteins that inactivates p53.

MATERIALS AND METHODS

Patients were selected on the basis of HPV infection, clinical history, positive PAP test and type of lesion. In situ PCR was performed on smear samples, in four steps: a) preparation on clean biobond-treated slides, b) permeabilisation and digestion; c) in situ PCR amplification; d) in situ hybridisation with a fluorescent probe.

RESULTS

In situ PCR analysis of the smears confirmed the results obtained by classic PCR and by in situ PCR of frozen sections.

CONCLUSION

In situ PCR on smears could be used in targeted-screening for young and post-menopausal women, as well as in the development of large scale studies to establish the connection among the presence of HPV, p53 polymorphisms and the risk of cervical cancer.

ABBREVIATIONS

PCR, polymerase chain reaction; OsO4, osmium tetroxide; HPV, human papilloma virus; PBS, phosphate-buffered saline; SDS, sodium dodecyl sulphate.

Address: Department of Experimental Medicine and Pathology, University La Sapienza, Rome, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.